Purpose of review To examine recent publications on lung transplantation for cystic fibrosis for changes in surgical techniques, selection criteria of patients, and impact on quality of life.
Introduction
Lung transplantation is the most aggressive therapy for end-stage lung disease in cystic fibrosis. As lung disease is the primary cause of death for 80% of cystic fibrosis patients [1 ] , lung transplantation is an important therapeutic option. Patients with cystic fibrosis are the third largest group of transplant recipients after patients with chronic obstructive lung disease and idiopathic pulmonary fibrosis [2] . The primary goal of transplant has always been to treat cystic fibrosis patients with end-stage lung disease for whom medical therapies have failed. The secondary goal has been to improve quality of life.
In 1983, a team at the University of Pittsburgh performed the first lung transplant for cystic fibrosis [3] [4] [5] . Following the early experience, multiple refinements in surgical technique, medications and selection criteria have gradually improved postsurgical survival [2] , as well as survival benefit compared with nontransplanted patients [6 ] . This review examines current lung transplantation options, selection criteria and impact on survival and quality of life for patients with cystic fibrosis.
Surgical options
The initial procedure was combined heart-lung transplant [3] [4] [5] . A variant was the domino procedure wherein a cystic fibrosis patient received a cadaveric heart-lung transplant and donated his or her healthy heart to a patient awaiting heart transplantation [7] . The rationale for this procedure was to avoid tracheal anastomosis complications. The procedure sometimes led to more efficient use of scarce donated organs. Transplantation of a heart into a cystic fibrosis patient with no preexisting cardiac disease, however, requires cardiopulmonary bypass with its inherent increased complication risks, and risks additional heart transplant-related complications for no additional gain in health compared to lung transplantation alone [8] .
Whole lung or double-lung block transplantation including a portion of the trachea was briefly used. The procedure was more difficult, however, and prone to anastomotic complications. It is no longer performed.
Bilateral sequential lung transplantation utilizes mainstem bronchial anastomoses, which eliminates tracheal anastomosis complications. It does not involve the heart and often permits transplant surgery without cardiopulmonary bypass. It avoids the risk of cardiac allograft vasculopathy, which may be as high as 16% after combined heart-lung transplantation [9 ] . Currently, cadaveric bilateral sequential lung transplantation is the predominant operative method. Heart-lung and domino transplant procedures continue to be performed at a few centers, with approximately the same outcomes as bilateral sequential lung transplantation [10, 11 ] . Double or bilateral lobar lung transplantation transplants lobes (usually lower lobes) from living donors into a transplant candidate who is unlikely to survive to receive an organ from a deceased donor. This type of surgical procedure can reduce the impact of the continuing shortage of donated organs for some patients [12] . Lobes from deceased (cadaveric) donors have also been transplanted. Split lung transplantation has been performed in cystic fibrosis children at a few centers in Europe [13] .
Organs from donors after cardiac death (nonheart-beating donors) may help increase the supply of donor lungs [14 ] . These organs have been used in countries where brain death has not been legally defined. In other locales where donated organs are scarce, lungs from nonheartbeating donors are under consideration for routine use. Potential use of these organs remains an active area of research within the US. Recipient outcome data are currently unavailable.
Patient selection
Guidelines for patient selection have evolved since the initial criterion of selecting patients with 'Deteriorating chronic respiratory failure' [5] . Observations of a high 2-year mortality among patients with cystic fibrosis with a forced expiratory volume in 1 s (FEV 1 ) less than 30% led to the recommendation to list these patients for lung transplantation [15] . An association between hypercarbia and early mortality suggested that patients with cystic fibrosis with hypercarbic respiratory failure also be considered for lung transplantation [15] . These recommendations were included in consensus guidelines from the International Society of Heart and Lung Transplantation and the American College of Chest Physicians for patients with cystic fibrosis, which were both published in 1998 [16, 17] . These guidelines suggest transplanting patients with an FEV 1 less than 30% of predicted, rapidly worsening lung disease or falling FEV 1 , increasing hospitalizations, massive hemoptysis, increasing cachexia, female gender, and resting room air blood gas with PaCO 2 greater than 50 mmHg. Some noted, however, that an FEV 1 less than 30% is not necessarily a strong enough predictor of mortality in cystic fibrosis to be used as a criterion for transplantation [18, 19] . The consensus guidelines also did not include precise suggestions for prioritizing the different individual criteria and did not include other factors that influence survival in cystic fibrosis [20] , making the guidelines more difficult to use and subject to interpretation. Nevertheless, a recent multicenter case series and analysis find that these guidelines are still a useful starting point for consideration of patients for lung transplantation [21 ] . Over the last few years, additional information allows consideration of patients with cystic fibrosis for lung transplantation by more precise groups and criteria.
Stable adult patients without Burkholderia cepacia
In 2001, we published a 5-year predicted survival model of cystic fibrosis based on data from the US Cystic Fibrosis Foundation Patient Registry. We evaluated outcomes of lung transplantation for patients with different predicted survivals [20, 22] . The analysis is most applicable to adult patients without Burkholderia cepacia infection who are not critically ill. Our analysis shows that patients with a 5-year predicted survival of less than 30% had significantly better survival with transplant than without, while patients with a greater than 50% 5-year survival prediction were likely to have decreased survival with transplantation. Recently, we found that adult patients with a 30-50% predicted survival have a modest survival benefit that is not discernible until more than 5 years after transplantation [6 ] .
The 5-year predicted survival model depends upon best FEV 1 percentage of predicted and total number of acute exacerbations up to five in the prior year, weight-for-age z-score, age, gender, diabetes, pancreatic sufficiency, and Staphylococcus aureus and B. cepacia infections. Predicted survival may be calculated using a worksheet obtained from the American Journal of Epidemiology web site (http://aje.oxfordjournals.org/cgi/data/153/4/345/ DC1/1) or by contacting the authors.
Stable pediatric patients without B. cepacia
Huddleston et al. [23] reported the results of lung transplantation in 207 children, of whom 89 were patients with cystic fibrosis. Five-year survival for pediatric transplant recipients was slightly better than historical adult transplant survival. Survival was not compared with a matched group of nontransplanted children, and thus survival benefit could not be estimated.
Using data from 124 children with cystic fibrosis accepted for lung transplantation, Aurora et al. [24] used Cox proportional hazards models with time-dependent covariates and found that lung transplantation reduces the hazard of death compared with survival while on the waiting list. The study shows that pediatric patients already selected for transplant may benefit with lung transplantation. The authors carefully noted that the study is specific to their local cohort of patients. Patients had an estimated life expectancy of 2 years or less based on lung function, various clinical and physiological measures, poor quality of life and no contraindications to transplantation. In a separate paper, the same group presents a survival model that may be helpful in identifying patients similar to those for whom they found a benefit with lung transplantation [25] . The model includes low height, FEV 1 %, low minimum oxygen saturation during a 12 min walk, high ageadjusted resting heart rate, young age, female gender, low plasma albumin, and low blood hemoglobin as predictors for poor prognosis [25] .
We compared survival of all children in the US that had transplants from 1991 through 2001 (184 patients) with nontransplanted controls (859 patients) stratified by their 5-year predicted survivals [6 ] . This analysis identifies pretransplantation factors that influence posttransplantation survival. The results show that patients younger than 18 had no survival benefit due to lung transplantation regardless of their 5-year predicted survivals.
These last results are at odds with the prior work of Aurora et al. [24] and evoke concern [26] that pediatric patients might be denied the opportunity for lung transplantation. These concerns underscore the need for increased caution in choosing and counseling pediatric patients for lung transplantation, and the need for additional study. The results may support a call for a prospective study of lung transplantation in pediatric patients with cystic fibrosis.
Critically ill patients
Mechanically ventilated patients with cystic fibrosis have an exceptionally low likelihood of prolonged survival, regardless of previous 5-year predicted survivals. Three groups have found that standard lung transplantation improves survival in mechanically ventilated cystic fibrosis patients [27] [28] [29] . The posttransplantation survival of these patients is similar to that of patients transplanted without an episode of respiratory failure and mechanical ventilation. In comparison with nontransplanted patients with cystic fibrosis with respiratory failure and on mechanical ventilation, transplanted patients have superior survival. Unfortunately, the difficulties of locating organs in a timely manner for intubated patients can be insurmountable.
One possibility in this situation is to explore living donor lobar lung transplantation [30] . Patients undergoing living donor lobar lung transplantation while mechanically ventilated and intubated have a worse outcome than spontaneously breathing recipients of living lobar transplants. This subgroup of patients with cystic fibrosis, however, had postoperative survival that was comparable with historical survival rates for lung transplantation in general [30] .
Patients infected with B. cepacia
Patients with end-stage lung disease and a 5-year predicted survival less than 30% may have such severe disease due to B. cepacia. Few such patients, however, were identified in the analysis of survival effect of transplant for patients stratified by 5-year predicted survival (unpublished). Thus the benefit of lung transplantation remains uncertain in this patient subset [22] . Multiple analyses have noted that posttransplantation survival is reduced by B. cepacia infection relative to noninfection [6 ,31-35] . Our own recent publication further suggests that posttransplant survival is reduced relative to nontransplanted survival with B. cepacia infection [6 ] . Nevertheless, it is unclear whether patients with B. cepacia infection might still benefit from lung transplantation because of uncertainty over the survival effects of different genomovars of Burkholderia. There is evidence that there are heterogeneous outcomes among individuals after infection with a single genomovar [36 ] , and thus some patients with B. cepacia may benefit from transplantation. The heterogeneous outcomes suggest that further study is needed before definitive statements can be made regarding lung transplantation and patients with cystic fibrosis and infection with B. cepacia.
Other identifiable patient groups
Several publications note that increased PaCO 2 is a marker of respiratory failure and increases mortality [15,21 ,37,38] . By itself, the PaCO 2 may be helpful in identifying patients appropriate to transplant. Whether PaCO 2 is an independent predictor of early mortality in cystic fibrosis or whether it is primarily covariant with other data such as FEV 1 is unknown, however.
The initial large series of lung transplants in cystic fibrosis patients noted that multiresistant Pseudomonas aeruginosa infections caused decreased survival relative to noninfected transplant recipients [3] . When specifically evaluated, however, these infections did not adversely affect survival of patients after transplantation [31] . Several recent case series of lung transplantation in cystic fibrosis that include patients infected with multiresistant bacteria do not report that these infections cause posttransplantation complications [21 ,39,40 ] .
Our recent study of pretransplantation factors that affect posttransplantation survival shows that cystic fibrosisrelated arthropathy predicts poor posttransplantation survival [6 ] . Arthropathy does not affect survival for nontransplanted patients [20] but appears to markedly reduce posttransplantation survival. The result was based on the poor posttransplantation survival of 15 patients with arthropathy compared with 830 patients without arthropathy. The lack of an established guideline for the diagnosis of cystic fibrosis-related arthropathy, however, makes this an uncertain criterion for excluding patients from consideration for lung transplantation.
The lung allocation score and patient selection for lung transplantation On 5 May 2005, the United Network for Organ Sharing (UNOS)/OPTN changed the waiting list for lung transplantation from the original seniority system to a system intended to rank patients 12 years of age or older by both acuity and utility. The Lung Allocation Score (LAS) includes measures of disease acuity, such as lung function, 6-min walk test and supplemental oxygen requirements, for patients with a variety of diseases. It incorporates a prediction of benefit defined as the difference between expected posttransplant survival days during 1 year posttransplantation minus expected survival days on the waiting list during 1 year of waiting. The LAS is not intended to predict survival in cystic fibrosis. The LAS will undergo continuous revision as additional experience is gained from implementation of the system (http://www.unos.org/SharedContentDocuments/ Calculation_Guide.pdf) [41] .
As the LAS is derived entirely from data collected from patients already on the waiting list for lung transplantation or data from transplanted patients, it does not have a direct impact on choosing patients most likely to benefit from transplantation. As it will be modified based on experience gained from wait-listing and posttransplantation data, it is likely to be heavily influenced by the patients that physicians actually refer for lung transplantation and enter into the waiting list for transplantation. Thus, physicians caring for patients with cystic fibrosis must still consider the various criteria listed above and make the decision to list for lung transplantation or not.
Quality of life and lung transplantation
Improved quality of life (QOL) has been a goal of lung transplantation since the first transplant. Two issues make objective assessment of improvements in QOL difficult, however. First, validated objective measurement tools for QOL specific for cystic fibrosis did not exist until recently [42] . Secondly, bias unavoidably arises posttransplantation that compromises comparison of QOL after transplantation with QOL pretransplantation. Mortality following lung transplantation is a competing risk that increases with time posttransplantation. Thus QOL for patients that die early after transplantation cannot be evaluated. One pragmatic approach is to consider QOL following transplantation conditioned on survival [43 ,44 ] . This approach answers questions asking what the QOL is for patients who survive particular intervals after transplantation. It cannot answer the direct question that asks how QOL will change due to transplantation. This subtle but important difference requires that discussions about QOL after transplantation include information that QOL is intricately intertwined with and dependent upon survival.
Existing studies, conditioned upon survival, show that in general patients with cystic fibrosis have a higher posttransplantation QOL than patients transplanted for other diagnoses. Apparent QOL for survivors wanes with length of time since transplantation and substantially further decreases with bronchiolitis obliterans or other complications that increase the burden of care, such as increasing hypoxemia and declining tolerance for physical activity [43 ,44 ] .
There is no information that can assist patients who are willing to sacrifice longer survival for improved quality of life. While current survival models for cystic fibrosis can predict whether a patient will likely have an increase or decrease in survival with transplantation [22] , no model can predict which patients will have an increase in QOL sufficient to justify a decrease in survival.
Conclusion
Hundreds of patients worldwide undergo lung transplantation for end-stage lung disease due to cystic fibrosis each year. Selection of patients may be easier now than in the past with the availability of survival prediction models [22] , and with information that certain groups of patients do poorly after transplantation. Patients with low 5-year predicted survival likely benefit from lung transplantation. Critically ill patients on mechanical ventilation likely benefit but donor lungs are often unavailable in time. Chronic hypercarbic respiratory failure may independently identify reasonable transplant candidates, but because of sparse survival studies, hypercarbia alone should not be used to choose patients.
Transplantation reduces survival for patients with high FEV 1 % or 5-year predicted survival, but questions remain for patients with other characteristics. Further study is needed to identify which subgroups, if any, of patients infected with B. cepacia species might benefit from transplantation. Similarly, arthropathy as a contraindication requires more study. Seemingly contradictory analyses concerning lung transplantation and children with cystic fibrosis require more study.
Improved QOL after lung transplantation remains tightly linked to survival and difficult to evaluate. Current information suggests that QOL increases after lung transplantation for survivors but that it decreases with time and complications such as bronchiolitis obliterans.
End-stage lung disease remains the primary cause of early death in cystic fibrosis. Until we make significant further progress in treating or preferably preventing end-stage lung disease in cystic fibrosis, lung transplantation will remain a considered choice for selected patients with cystic fibrosis.
